Literature DB >> 1966928

Leukotriene B4 and oral cancer.

I E el-Hakim1, J D Langdon, J T Zakrzewski, J F Costello.   

Abstract

The quantitation of leukotriene B4 (LTB4) in induced squamous cell carcinoma (SCC) of the Syrian hamster cheek pouch and histologically proven human oral SCC was investigated by a combination of reverse phase-high performance liquid chromatography (RP-HPLC) and radioimmunoassay (RIA). Healthy tissue obtained from these same patients and animals treated with vehicle alone were used as controls. From both animal and human studies our results show a 10 to 30 fold increase in the levels of LTB4 found in tumour compared to control tissue. Furthermore, this dihydroxy acid was not detected in the mucosal tissue of normal subjects undergoing routine surgery. Since LTB4 is a potent inflammatory mediator and modulator of immune responses, its presence at biologically active concentrations in human squamous cell carcinoma suggests a possible role in the pathogenesis of head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966928     DOI: 10.1016/0266-4356(90)90078-y

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  6 in total

1.  LTA4H regulates cell cycle and skin carcinogenesis.

Authors:  Naomi Oi; Hiroyuki Yamamoto; Alyssa Langfald; Ruihua Bai; Mee-Hyun Lee; Ann M Bode; Zigang Dong
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

2.  Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15- oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo.

Authors:  Yuhua Zhao; Chu-Chun Weng; Min Tong; Jingyan Wei; Hsin-Hsiung Tai
Journal:  Lung Cancer       Date:  2009-09-17       Impact factor: 5.705

3.  Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.

Authors:  Louise Y Y Fong; Yubao Jiang; Maurisa Riley; Xianglan Liu; Karl J Smalley; Denis C Guttridge; John L Farber
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

Review 4.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.

Authors:  Peiying Yang; Zheng Sun; Diana Chan; Carrie A Cartwright; Mary Vijjeswarapu; Jibin Ding; Xiaoxin Chen; Robert A Newman
Journal:  Carcinogenesis       Date:  2008-08-06       Impact factor: 4.944

Review 6.  Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets.

Authors:  Carla S S Teixeira; Sérgio F Sousa
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.